Chronic obstructive pulmonary disease (COPD) patients may suffer from symptoms of anxiety and depression.
Introduction
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible, is progressive and is associated with an abnormal inflammatory response of the lung to noxious particles or gases. 1 Additionally, COPD is associated with systemic alterations in biochemistry and organ function, like weight loss, muscle wasting and changes in muscle metabolism. 2, 3 Moreover, patients with COPD may also experience a higher prevalence of psychological distress, like symptoms of anxiety and depression, than the general healthy population. [4] [5] [6] [7] COPD is known to have a negative impact on disease-specific health status. [8] [9] [10] [11] Disease-specific health status has been shown to be more strongly associated with psychological well-being than with the impaired lung function. 12 Symptoms of anxiety and depression may have widespread consequences for COPD patients. For example, symptoms of depression in patients with COPD are associated with worse prognosis of survival, more days of hospitalization and less successful smoking cessation. [13] [14] [15] [16] Previous research in COPD patients suggests a relationship between symptoms of anxiety or depression and female gender, 15, 17, 18 smoking, 17 younger age, 19 body mass index (BMI), 13, 15, 18 dyspnea 20,21 and living alone. 4 However, the aforementioned possible determinants of clinically relevant symptoms of anxiety and depression have mainly been studied in sizelimited samples of COPD patients in the hospital or primary care setting.
COPD patients who are symptomatic or who complain of having decreased daily life activity at outpatient consultation with chest physician, even if receiving optimum drug treatment, need referral to a specialized rehabilitation centre. 22 Although scientific evidence is scarce, recent international guidelines on pulmonary rehabilitation recommend, based on current practice and expert opinion, the inclusion of psychosocial interventions as a component of comprehensive pulmonary rehabilitation programs for COPD patients. 23 Although depression has been shown to be a risk factor for failure of pulmonary rehabilitation, 24 knowledge concerning the prevalence and determinants of clinically relevant symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation is scarce. Previously, clinically relevant symptoms of anxiety or depression were found in 28% to 38% and 15% to 42% of COPD patients entering pulmonary rehabilitation, respectively. 25, 26 Enhanced recognition of symptoms of anxiety and depression may be the first step leading to effective treatment of these symptoms and improvement in physical functioning and disease-specific health status. [27] [28] [29] The aim of the present cross-sectional study was to determine the prevalence and determinants of clinically relevant symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Finally, the use of antidepressant and anxiolytic drugs has been examined in COPD patients entering pulmonary rehabilitation with and without clinically relevant symptoms of anxiety or depression.
Methods Patients
Patients with mild to very severe COPD admitted between January 2005 and October 2007 to Ciro, centre of expertise for chronic organ failure, for a comprehensive interdisciplinary pulmonary rehabilitation program have been included in this study. The diagnosis of COPD was based on the definition provided by the Global initiative for chronic Obstructive Lung Disease (GOLD). 1 
Instruments
As part of the clinical routine, the following parameters have been assessed prospectively: pulmonary function, arterial blood gases, body composition, exercise capacity, mood status and disease-specific health status. Additionally, current smoking status, daily coughing, dyspnea and use of long-term oxygen therapy (LTOT) have been assessed. Co-existing morbidities have been assessed by the Charlson comorbidity index (a weighted index that takes into account the number and seriousness of comorbid disease(s)). 30 Finally, current antidepressant and anxiolytic medication use was recorded. All tests were in accordance with the World Medical Association declaration of Helsinki. 31 Ethical approval was not indicated because all of the tests were done as part of the clinical routine and retrospectively analyzed. Approval from the institution was obtained to use patients' records for the study and patients' confidentiality was maintained. Some of the patients were part of a previous study. 21 
Pulmonary function and arterial blood gases
Forced expiratory volume in the first second (FEV 1 ) and forced vital capacity (FVC) have been calculated from the flow-volume curve using spirometry and expressed as a percentage of reference values. 32 Arterial oxygen tension (PaO 2 ), arterial carbon dioxide tension (PaCO 2 ) and arterial oxygen saturation (SaO 2 ) have been analyzed with a blood-gas analyzer.
Body composition
Height and weight were measured and mean BMI was calculated. Body composition was assessed by using single-frequency bioelectrical impedance assessment after overnight fasting. 33 Fat-free mass was calculated by using COPD-specific equations. 34 A priori, a BMI below 21 kg/m 2 and a fat-free mass index (FFMI; fatfree mass in kilogram divided by squared height in meters) below 15 kg/m 2 for female and below 16 kg/m 2 for male patients have been defined as abnormally low. 35 
Exercise capacity
Functional exercise capacity has been assessed by using two 6-minute walking distance (6MWD) tests performed on 2 consecutive days. 36 The results were expressed in percentage of predicted values for healthy elderly of comparable age. Values below 82% of predicted values were considered as abnormally low. 37 
Symptoms of anxiety and/or depression and disease-specific health status
Symptoms of anxiety and/or depression have been assessed by using the Hospital Anxiety and Depression Scale (HADS), a validated and reliable measurement instrument used widely in medically ill patients to screen for clinically relevant symptoms of anxiety and/or depression. 38 The HADS is a self-administered questionnaire, consisting of 14 questions. The HADS is divided in an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both containing seven items. Total scores for each subscale can range from 0 (optimal) to 21 (worst) points. A score equal to or greater than 10 for anxiety and/or depression has been defined as abnormally high and may indicate the presence of clinically relevant symptoms of anxiety and/or depression. 38 For assessment of disease-specific health status, the St. George Respiratory Questionnaire (SGRQ) has been used. The SGRQ is a self-administered questionnaire, designed for measurement of health impairment in patients with COPD. The SGRQ consists of 50 items, divided in three domains (symptoms, activities and impact), providing three domain scores. A total score is also provided. Scores can range from 0 (optimal) to 100 points (worst). 39 
Statistics
All statistics were performed using SPSS 15.0. Categorical variables have been described as frequencies, while continuous variables have been tested for normality and are presented as mean and standard error of the mean (SEM). The percentage of patients with a HADS-A and/or HADS-D score 10 points has been computed. Differences in proportions of patients with a HADS-A or HADS-D score 10 points between GOLD stages (GOLD stage I/II vs III, GOLD stage I/II vs IV and GOLD stage III vs IV) have been assessed by using Chi square test. Differences in SGRQ scores between patients with a HADS-A or HADS-D score 10 points and patients with a HADS-A or HADS-D score <10 points have been determined by using independent sample T test. For differences in the use of anxiolytic and antidepressant drugs in patients with and without symptoms of anxiety and depression, Chi square test has been used. The relationship between symptoms of anxiety or depression and demographic and clinical characteristics has been assessed by performing logistic regression analysis with the score on the HADS-A and HADS-D (10 points or <10 points) as the dependent variable and all the demographic and clinical variables as covariates. All covariates were entered as categorical variables by forced entry method. The continuous variables FEV 1 and age were dichotomized according to the mean FEV 1 (39% of predicted) and mean age (65 years) as reported in the Cochrane review of Lacasse and colleagues. 40 In addition, subgroup analyses have been performed including only the patients without previous use of anxiolytic and/or antidepressant drugs.
A priori, a two-sided level of significance was set at p 0.05. 41 
Results

General patient characteristics
A total of 701 patients (280 female patients, 39.9%) were included in this study ( 
Symptoms of anxiety and/or depression and disease-specific health status
The mean score on HADS for anxiety was 7.6 (0.2) points and for depression 7.2 (0.2) points. For anxiety, 225 patients (32.1%) had a score 10 points. For depression, 192 patients (27.4%) had a score 10 points and 124 of the aforementioned patients (17.7%) had a score 10 points for both anxiety and depression. In total, 41.8% of the patients reported symptoms of anxiety or symptoms of depression or both. The score of HADS-A was positively related to the score of HADS-D (r ¼ 0.62, p < 0.0001).
A statistically significant higher proportion of patients with GOLD stage IV (37.9%) than patients with GOLD stage I or II (29.0%) had HADS-A scores 10 points (p ¼ 0.05), while differences with GOLD stage III (29.8%) were not statistically significant. Additionally, a statistically significant higher proportion of patients with GOLD stage IV (34.2%) had HADS-D scores 10 points than patients with GOLD stage I or II (23.0%) or GOLD stage III (25.3%; p < 0.05; Figure 1 ).
Patients with HADS-A or HADS-D scores 10 points had statistically significant and clinically relevant worse scores on all the domains of the SGRQ than patients with HADS-A or HADS-D score <10 points (p < 0.01; Figure 2 ). 42 
Anxiolytic and antidepressant drugs
In total, 110 patients (15.7%) used anxiolytic drugs (benzodiazepines: n ¼ 109; buspirone: n ¼ 1 
Abbreviations: Forced expiratory volume in the first second (FEV 1 ); forced vital capacity (FVC); resting arterial oxygen tension (PaO 2 ); resting arterial carbon dioxide tension (PaCO 2 ); Body mass index (BMI); Fat-free mass index (FFMI); 6 minute walking distance (6MWD) a Values reported as mean (standard error of the mean, SEM). subgroup, a higher proportion of patients with clinically relevant symptoms of anxiety suffer from coughing (78.0%) than patients without clinically relevant symptoms of anxiety (52.9%; p < 0.05 in univariate analysis).
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Furthermore, patients using antidepressant and/or anxiolytic drugs who report clinically relevant symptoms of depression (n ¼ 81) and patients who do not report clinically relevant symptoms of depression (n ¼ 89) are comparable with respect to gender, age, FEV 1 , marital status, Charlson index, LTOT, dyspnea, coughing, 6MWD, BMI, FFMI and smoking status.
Determinants of symptoms of anxiety and/or depression
The prevalence of clinically relevant symptoms of anxiety (Table 2 ) and depression (Table 3) has been calculated in several subgroups of patients. The crude and adjusted odds ratio (OR) for the influence of each demographic and clinical variable on the HADS scores has been calculated using logistic regression analysis. Patients at risk of having clinically relevant symptoms of anxiety were female or those who used anxiolytic and/or antidepressant drugs (p < 0.05). Age, FEV 1 , marital status, co-existing morbidities, use of LTOT, dyspnea, daily coughing, exercise capacity, BMI, FFMI and smoking status were not associated with HADS-A 10 points. Patients at risk for having clinically relevant symptoms of depression had a BMI <21 kg/m 2 , experienced dyspnea at mild exercise or at rest or used anxiolytic and/or antidepressant drugs (p < 0.05). Gender, age, FEV 1 , marital status, co-existing morbidities, use of LTOT, daily coughing, exercise capacity, FFMI and smoking status were not associated with HADS-D 10 points.
Subgroup analyses have been performed including only the patients without previous use of anxiolytic and/or antidepressant drugs (n ¼ 531). These analyses have shown that also in this subgroup, female patients are more at risk of having clinically relevant symptoms of anxiety (adjusted OR: 2.94 [95% CI: 1.84-4.72]). In addition, in this subgroup, patients who experience dyspnea at mild exercise or at rest are more likely to experience clinically relevant symptoms of anxiety (adjusted OR: 2.48 [95% CI: 1.23-4.76]).
For clinically relevant symptoms of depression, findings are comparable with the findings from the analyses including patients with previous use of anxiolytic and/or antidepressant drugs. Patients without previous use of anxiolytic and/or antidepressant drugs at risk for development of clinically relevant symptoms of depression are patients who experience dyspnea at minimal exertion or at rest (adjusted OR: 3.89 [95% CI: 1.58-9.62]) or patients with a BMI <21 kg/m 2 (adjusted OR: 2.38 [95% CI: 1.29-4.41]).
Discussion
Key findings
The present study is the first to examine the prevalence of clinically relevant symptoms of anxiety and depression in a large cohort of COPD patients entering pulmonary rehabilitation and to examine the relationship with 14 possible determinants by logistic regression analyses.
This study shows that 41.8% of the COPD patients entering pulmonary rehabilitation experience clinically relevant symptoms of anxiety and/or depression, which are associated with impaired disease-specific health status. Patients at risk of having symptoms of anxiety are women or those who use anxiolytic and/ or antidepressant drugs. Patients at risk of having clinically relevant symptoms of depression experience dyspnea, have a low BMI or use anxiolytic and/or antidepressant drugs.
Symptoms of anxiety and/or depression and disease-specific
health status. In the present study, mean HADS scores and the prevalence of clinically relevant symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation were in line with previous findings. 25, 26, 43 In fact, the present data show again that patients entering pulmonary rehabilitation frequently experience clinically relevant symptoms of anxiety and depression.
The present study has shown that symptoms of anxiety and/or depression are associated with impaired disease-specific health status, measured by the SGRQ (on average 2.5 times the minimum clinically important difference of 4 units) in COPD patients entering pulmonary rehabilitation. These findings are consistent with previous studies demonstrating a relationship between symptoms of anxiety and depression and impaired health status in outpatients with COPD and patients hospitalized with an acute COPD exacerbation. 10, 15, 17, [44] [45] [46] Determinants of symptoms of anxiety. The present study shows that clinically relevant symptoms of anxiety are more common in female COPD patients. This is in accordance with previous studies in elderly outpatients with COPD and COPD patients admitted to Abbreviations: Forced expiratory volume in the first second (FEV 1 ); long-term oxygen therapy (LTOT); 6 minute walking distance (6MWD); body mass index (BMI); fat-free mass index (FFMI); Hospital Anxiety and Depression Scale, anxiety subscale (HADS-A); odds ratio (OR); confidence interval (CI); N¼701. a p < 0.05.
hospital for an acute exacerbation. 15, 17 Symptoms of anxiety are not associated with age, lung function, marital status, co-existing morbidity, LTOT, dyspnea, daily coughing, exercise capacity, body composition or smoking status. This also is in line with previous findings, although Gudmundsson and colleagues have found that anxiety is more common in current smokers. 17 Cleland and colleagues have shown a higher prevalence of anxiety in younger primary care COPD patients and no statistically significant difference for gender. 19 This could probably be explained by the different cut-off value for age (60 years) used in their analysis. Yohannes and co-workers did show that elderly COPD patients with a low BMI suffered more from anxiety. However, a different measurement instrument for anxiety (Geriatric Mental State Schedule) was used. 15 Determinants of symptoms of depression. The present study has shown that symptoms of depression are more common in patients who experience more severe dyspnea. The relationship between sensations of dyspnea and higher scores on the HADS in COPD patients has been shown before. 20, 21 Moreover, the relationship between depression and dyspnea has also been shown before in elderly patients with congestive heart failure. 47 Whether or not this is a causal relationship remains unknown. Clinically relevant symptoms of depression are more common in patients with a low BMI. This has previously been shown in COPD patients admitted to hospital for an acute COPD exacerbation 13 , while in primary care patients suffering from mild-to-moderate COPD depression was related with BMI>25kg/m 2 . 18 In the present study, clinically relevant symptoms of Abbreviations: Forced expiratory volume in the first second (FEV 1 ); long-term oxygen therapy (LTOT); 6 minute walking distance (6MWD); body mass index (BMI); fat-free mass index (FFMI); Hospital Anxiety and Depression Scale, depression subscale (HADS-D); odds ratio (OR); confidence interval (CI); N ¼ 701. a p < 0.05.
depression are not associated with gender, age, lung function, marital status, co-existing morbidity, LTOT, daily coughing, exercise capacity or smoking status. The present findings differ from those in other studies in some respects. For instance, previous research revealed a higher prevalence of symptoms of depression in female patients with mild-to-moderate COPD in primary care, 18 a higher prevalence of depression in younger COPD patients in primary care, 19 an association of symptoms of depression with current smoking in COPD patients being discharged after hospitalization 17 and a weak negative association between HADS scores and exercise capacity in patients with severe COPD entering pulmonary rehabilitation. 25 Additionally, Van Manen and colleagues found that COPD patients in primary care who lived alone were more likely to experience symptoms of depression, measured by the Centers for Epidemiologic Studies Depression scale (CES-D). 4
Diagnosis and treatment
Although symptoms of anxiety and depression may occur frequently in patients with COPD, they often remain un(der)diagnosed and un(der)treated. 46, 48 Several explanations have been hypothesized, like patients' unwillingness to report psychological symptoms, time constraints or priorities of the specialist involved in treatment of the patient, difficulty in distinguishing pathological psychological symptoms from a normal response to stressful physical illness and overlap or close association of somatic symptoms of anxiety or depression and symptoms due to COPD. 15, 27, 46, [48] [49] [50] Previous research has shown that patients with symptoms of anxiety and/or depression can benefit from an interdisciplinary pulmonary rehabilitation program. 25, 43 Indeed, recent findings suggest that comprehensive pulmonary rehabilitation is significantly more effective than standard pharmacological care for the reduction of symptoms of anxiety and depression in older patients with moderate-to severe COPD. 51 However, Garrod and colleagues demonstrated that depressed patients are considerably more at risk of drop-out from pulmonary rehabilitation than non-depressed patients. 24 This emphasizes even more the importance of early recognition of patients with symptoms of anxiety and depression entering pulmonary rehabilitation and the importance of paying more attention to these symptoms during pulmonary rehabilitation.
In the present study, the prevalence of antidepressant drug use is comparable to the findings of Kim and colleagues, while the use of anxiolytic drugs in our study is higher than in their study. 45 This could probably be explained by the fact that all patients included in the study of Kim were male and the present study shows that symptoms of anxiety are more prevalent in female than in male patients. Randomized-controlled clinical trials concerning the effectiveness and safety of the use of antidepressant or anxiolytic medication in patients with COPD are scarce. Further research in COPD patients on the effects of anxiolytic and antidepressant medication on symptoms of anxiety and depression, side-effects and safety is needed.
Recent guidelines on pulmonary rehabilitation have suggested that patients may benefit from the addition of psychosocial interventions to a pulmonary rehabilitation program. 23 However, evidence is scarce. A randomized controlled trial of 30 patients with COPD has shown that including a weekly psychotherapy session in a 12-week outpatient pulmonary rehabilitation program can reduce symptoms of anxiety and depression. 52 Further research to the effect of psychotherapy as a part of pulmonary rehabilitation is needed to determine whether or not / and to what extent the addition of psychotherapy to pulmonary rehabilitation can improve symptoms of anxiety and/or depression in patients with COPD and if so, which patients can benefit from psychotherapy.
Limitations of the present study
The present study has some limitations. Preferably, healthy controls should have been included in the present study to compare the prevalence of symptoms of anxiety and/or depression between patients with COPD and healthy controls. However, the internationally well-established cut-off value for HADS-scores of 10 points has been used to determine the presence of clinically relevant symptoms of anxiety and depression. 25, 26, 28, 38 Nevertheless, in the currently available literature, other cut-off values have been used for the HADS in COPD patients, like 8 points 13,17 or 9 points, 43 which could have led to higher prevalence rate of clinically relevant symptoms of anxiety and depression in the present study. However, Zigmond and Snaith recommend the use of cut-off 10 or 11 to identify patients with high probability of a mood disorder. 38 Additionally, many instruments exist for the measurement of symptoms of anxiety and/or depression, which may have altered the results of this study.
Other screening tools for symptoms of depression in COPD patients are for example the Primary Care Evaluation of Mental Disorders (PRIME-MD) patient health questionnaire, Beck Depression Inventory, CES-D or Geriatric Depression Scale. 29 Other available screening tools for symptoms of anxiety are the Depression Anxiety Stress Scale and Beck Anxiety Inventory. 29 Nowadays, no consensus exists for the most appropriate screening tool for symptoms of anxiety and/or depression in COPD patients. 29 Nevertheless, the HADS has shown to be a reliable and international frequently used psychological measurement instrument for COPD patients. 29 Questions are based on psychological symptoms and do not refer to symptoms of anxiety or depression that could also arise from a somatic disease. However, the HADS is a screening tool for symptoms of anxiety and depression and not an instrument for diagnosing an anxiety disorder or major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision; DSM-IV-TR). Nevertheless, the present study has shown that patients with clinically relevant symptoms of anxiety and/or depression have an impaired disease-specific health status. Moreover, previous studies have shown that pulmonary rehabilitation may improve symptoms of anxiety and/or depression and disease-specific health status, 25, 26, 43, 51, 53 and also that symptoms of depression may be a risk-factor for failure of pulmonary rehabilitation. 24 Therefore, it is of major importance to identify patients who suffer from clinically relevant symptoms of anxiety and/or depression. Indeed, in patients with clinically relevant symptoms of anxiety and/or depression, further psychiatric examination (e.g. structured clinical interview following the DSM-IV-TR) can be recommended for identifying patients with an anxiety disorder or major depressive disorder.
Finally, the present study has only included COPD patients entering pulmonary rehabilitation, which may limit the external validity of the present findings.
Conclusions
Patients with COPD entering pulmonary rehabilitation may suffer from clinically relevant symptoms of anxiety and/or depression. The poor diseasespecific health status of patients with symptoms of anxiety and/or depression emphasizes the importance of identifying these patients. Special attention needs to be paid to female patients, patients with a low BMI, patients who experience dyspnea at mild exercise or at rest and patients who use anxiolytic and/or antidepressant drugs. Future studies are warranted to evaluate the effect of psychotherapy and/or pharmacotherapy as part of interdisciplinary comprehensive pulmonary rehabilitation in COPD.
